Effect of [1,3-di-n-butyl-7-(2-oxopropyl)-xanthine] (denbufylline), a low Km phosphodiesterase inhibitor, on striatal acetylcholine release in the rat: analysis using cerebral microdialysis.
Effect of oral and intraperitoneal administrations of [1,3-di-n-butyl-7-(2-oxopropyl)-xanthine] (denbufylline) on acetylcholine (ACh) content and release in the rat striatum was investigated. Denbufylline (3, 10 and 30 mg/kg, p.o.) decreased striatal ACh contents in a dose-dependent manner. Denbufylline administration (30 mg/kg, i.p.) produced no significant change in the spontaneous release of ACh, while it increased a high potassium-evoked ACh release in the striatum. These results suggest that denbufylline may be a drug inducing the increased release of ACh in the brain.